Galectin Therapeutics (GALT) EBITDA (2010 - 2026)
Galectin Therapeutics (GALT) posted quarterly EBITDA of -$4.1 million for Q1 2026, up 48.37% year-over-year from -$2.7 million in Q1 2025, and down 21.16% quarter-over-quarter from -$3.4 million in Q4 2025.
Powered by 
Analysis
Galectin Therapeutics (GALT) EBITDA (2010 - 2026) Analysis & Trends
Galectin Therapeutics' EBITDA history runs 17 years deep, the most recent figure standing at -$4.1 million for Q1 2026.
- In Q1 2026, EBITDA rose 48.37% year-over-year to -$4.1 million; the TTM figure through Mar 2026 stood at -$16.3 million (up 60.02% YoY), while the FY2025 annual figure was -$20.1 million, up 52.67% from the prior year.
- EBITDA for Q1 2026 stood at -$4.1 million, down from -$3.4 million in the prior quarter.
- The five-year high for EBITDA was -$3.4 million in Q4 2025, with the low at -$12.4 million in Q4 2024.
- The 5-year median for EBITDA is -$9.2 million (2023), against an average of -$8.4 million.
- The sharpest annual moves came in 2022 and 2025: EBITDA slumped 57.27% in 2022, then jumped 72.92% in 2025.
- Galectin Therapeutics' EBITDA stood at -$10.6 million in 2022, then grew by 10.08% to -$9.6 million in 2023, then dropped by 29.99% to -$12.4 million in 2024, then surged by 72.92% to -$3.4 million in 2025, then slipped by 21.16% to -$4.1 million in 2026.
- Business Quant data shows GALT's EBITDA at -$4.1 million in Q1 2026, -$3.4 million in Q4 2025, and -$4.2 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn | -815.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | -505.13 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 325.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 133.12 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Galectin Therapeutics | 303.68 Mn | 303.68 Mn | - | -3.98 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3.98 Mn |
| Mar 31, 2026 | -4.08 Mn |
| Dec 31, 2025 | -3.37 Mn |
| Sep 30, 2025 | -4.20 Mn |
| Jun 30, 2025 | -4.63 Mn |
| Mar 31, 2025 | -7.90 Mn |
| Dec 31, 2024 | -12.43 Mn |
| Sep 30, 2024 | -9.07 Mn |
| Jun 30, 2024 | -11.29 Mn |
| Mar 31, 2024 | -9.65 Mn |
| Dec 31, 2023 | -9.56 Mn |
| Sep 30, 2023 | -9.17 Mn |
| Jun 30, 2023 | -9.00 Mn |
| Mar 31, 2023 | -10.34 Mn |
| Dec 31, 2022 | -10.63 Mn |
| Sep 30, 2022 | -8.12 Mn |
| Jun 30, 2022 | -9.66 Mn |
| Mar 31, 2022 | -9.94 Mn |
| Dec 31, 2021 | -7.43 Mn |
| Sep 30, 2021 | -8.24 Mn |